News AbbVie signs $225m 'immunoneurology' deal to tackle Alzheime... Partnership will use novel approach to treating Alzheimer's.
News Novartis sets sights on new oral MS drug after phase 3 wins Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
